Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine

Abstract We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Open Forum Infectious Diseases 2024-02, Vol.11 (2), p.ofad673
Hauptverfasser:	Babu, Tara M, Shen, Xiaoying, McClelland, R Scott, Wang, Zijun, Selke, Stacy, Wilkens, Chloe, Hauge, Kirsten A, McClurkan, Christopher L, Goecker, Erin, Laing, Kerry J, Koelle, David M, Greninger, Alexander L, Nussenzweig, Michel C, Montefiori, David C, Corey, Lawrence, Wald, Anna
Format:	Artikel
Sprache:	eng
Schlagworte:	B cells Coronaviruses Health aspects Pharmaceutical industry RNA Severe acute respiratory syndrome Vaccines Vaccines and Immunization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.
ISSN:	2328-8957 2328-8957
DOI:	10.1093/ofid/ofad673